Atypical Antipsychotic Medication in Pediatric Patients
Funded by the Wisconsin Department of Health Services, Wis.Stat.20.435 and 51.442 and in part from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a 5-year cooperative agreement.
This series of online modules provides education about psychiatric diagnoses and treatment, with an educational emphasis on psychopharmacology, to Primary Care Clinicians. Given the shortage of Child Psychiatrists nationally and in Wisconsin, in particular, Primary Care Clinicians are being tasked increasingly with assessing and treating children with mental health issues. Primary Care Clinicians report having had insufficient education about psychiatric diagnoses and treatment during their residency training, but they increasingly are asked to perform mental health assessments and to provide treatment for their patients. The goal is to provide education about psychiatric assessment and treatment to Primary Care Clinicians, thereby supporting them in their role as front-line providers of mental health care to children.
- Primary Care Clinicians
- Allied Health Care Professionals
Participants who engage in this educational activity will be able to:
- Describe which pediatric conditions are often treated with atypical antipsychotic medications
- Identify several different atypical antipsychotic medications that are used for this purpose
- Describe possible side effects and monitoring guidelines for these medications
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
Gabriella Hangiandreou, MD
Pediatric Psychiatry, Psychiatry, Pediatric Psychiatry
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Medical College of Wisconsin, Inc. is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for 12.0 contact hours of continuing education (which includes 3.0 hours of pharmacology).
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 12.00 AAPA Category 1 CME credits. Approval is valid for one year from 12/01/2023. PAs should only claim credit commensurate with the extent of their participation.
This session Atypical Antipsychotic Medication in Pediatric Patients is approved for 1 Enduring Material AAFP Prescribed credit.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.